KAI407, a Potent Non-8-Aminoquinoline Compound That Kills Plasmodium cynomolgi Early Dormant Liver Stage ParasitesIn Vitro
Primaquine
Atovaquone
Plasmodium (life cycle)
Serial dilution
DOI:
10.1128/aac.01927-13
Publication Date:
2013-12-24T04:23:33Z
AUTHORS (26)
ABSTRACT
Preventing relapses of Plasmodium vivax malaria through a radical cure depends on use the 8-aminoquinoline primaquine, which is associated with safety and compliance issues. For future eradication strategies, new, safer curative compounds that efficiently kill dormant liver stages (hypnozoites) will be essential. A new compound potential activity was identified using low-throughput assay in vitro-cultured hypnozoite forms cynomolgi (an excellent accessible model for vivax). In this assay, primary rhesus hepatocytes are infected P. sporozoites, exoerythrocytic development monitored presence compounds. Liver stage cultures fixed after 6 days stained anti-Hsp70 antibodies, relative proportions small (hypnozoite) large (schizont) to untreated controls determined. This used screen series 18 known antimalarials 14 non-8-aminoquinolines (preselected blood and/or activity) three-point 10-fold dilutions (0.1, 1, 10 μM final concentrations). novel compound, designated KAI407 showed an profile similar primaquine (PQ), killing earliest parasites become either hepatic schizonts or hypnozoites (50% inhibitory concentration [IC50] hypnozoites, KAI407, 0.69 μM, PQ, 0.84 μM; developing stages, 0.64 0.37 μM). When given as causal prophylaxis, single oral dose 100 mg/kg body weight prevented parasitemia mice. From these results, we conclude may represent class prophylaxis potentially cure.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (53)
CITATIONS (63)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....